Oliver Sexton

Investment Director, UKI2S

Oliver joined UKI2S in 2014 to manage its life science and healthcare investments. He was the founding investor in Quethera (acquired by Astellas) and is on the board of various biotech companies including Gyreox and Ikarovec. He invests predominantly in biotech but the fund can also back agritech and clean tech companies.

Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics where he managed BD and licensing. He has a background in strategy analysis and consultancy in London and New York including managing a team of buy-side analysts.

Leonardo Royal Hotel London Tower Bridge

20 October 2022